Article
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2021
Adib Elio, Klonowska Katarzyna, Giannikou Krinio, Do Khanh T, Pruitt-Thompson Solida, Bhushan Ketki, Milstein Matthew I, Hedglin Jennifer, Kargus Katherine E, Sholl Lynette M, Tsuji Junko, Hyman David M, Sisk Anne, Shapiro Geoffrey I, Vargas Hebert A, Harding James J, Voss Martin H, Iyer Gopa, Kwiatkowski David J
Abstract excerpt
PURPOSE: This was a multicenter, histology-agnostic, single-arm prospective phase II trial of therapeutic activity of everolimus, an oral mTORC1 inhibitor, in patients with advanced solid tumors that harbored TSC1/TSC2 or MTOR mutations. PATIENTS AND METHODS: Patients with tumors with inactivating TSC1/TSC2 or activating MTOR mutations identified in any Clinical Laboratory Improvement Amendments (CLIA)-certified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.